KIN-3248

News alerts, weekly reports and conference planners

Company:

Xoma

Drug class:

FGFR inhibitor

Related drugs:

FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B
FGFR2 mutation	Gastric Cancer	FGFR2 mutation	Gastric Cancer	KIN-3248 Sensitive: D – Preclinical KIN-3248 Sensitive : D	KIN-3248 Sensitive: D – Preclinical KIN-3248 Sensitive : D

Associations
(3)